Excited to share our new study from @asharpmedonc.bsky.social lab at @icr.ac.uk 🔬✨ We identify therapeutic strategies to target MCL1 and BCLXL in lethal prostate cancer. So happy to have to co-led this work with my colleagues and friends #DanWestaby & @inesfigueiredo.bsky.social 🔗 bit.ly/4oHSvNx

It’s my first #Movember! 🥸 As a prostate cancer researcher at @icr.ac.uk (and someone whose family’s been affected by the disease), I’m growing a moustache to support awareness and research this month. 💙 Join me on this Mo journey! 👨🏻‍🔬 movember.com/m/15464015?m...

The importance of fundamental research! 🧪🧫👩‍🔬👨‍🔬

Our fantastic @prostateukprofs.bsky.social career development fellow @juanjimenezvacas.bsky.social takes a closer look at a potential new treatment approach for #ProstateCancer that has stopped responding to existing therapies ⬇️.

This was my last meeting with the @ese-eyes.bsky.social News editorial committee, the newsletter of the early career group of the @esendocrinology.bsky.social Grateful for the journey & everyone who made it special. Time to pass the torch to the next generation to keep driving it forward!

🚨 Delighted to share our latest paper, from @asharpmedonc.bsky.social team in collaboration with Johann de Bono’s team at @icr.ac.uk and international colleagues, published in Nature Communications @natureportfolio.nature.com Read here: bit.ly/477pYt7 🧵1/4

Teamwork makes the dream works! Thank you, PCUK, for your support! @prostatecanceruk.bsky.social @prostateukprofs.bsky.social

Could targeting MCL1 be a new treatment approach for hormone therapy-resistant #ProstateCancer? A study in @natcomms.nature.com by @juanjimenezvacas.bsky.social, @asharpmedonc.bsky.social and the @icr.ac.uk team explores precision therapy strategies. Grab a ☕ and read: doi.org/10.1038/s414...